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Sunmary From November 1976 to June 1982, a randomised clinical trial was carried out at the Christie
Hospital, Manchester, to test the clinical efficacy of tamoxifen (TAM) as an adjuvant to surgery for patients
with operable breast carcinoma. Following surgery, premenopausal women were randomly allocated to have
either TAM 20mgday- 1 for one year or an irradiation menopause (the previous standard treatment).
Postmenopausal women had TAM 20mgday-' for one year or no further treatment (Controls).
A total of 1005 patients were entered into the trial of whom 961 are evaluable at 10 years from the
inception.
At 10 years the analysis shows no significant difference in overall and disease free survival between
premenopausal women given TAM or an irradiation menopause. For premenopausal node negative patients
there would appear to be a trend in favour of the TAM treated patients with a 93% ten year survival vs. 82%
for the irradiation menopause group (P=0.09).
When the disease free survival of all 961 patients is analysed, allowing for node status, then there is a
marked trend in favour of the TAM treated patients (P=0.07).
Of the patients originally allocated to TAM 47% had an irradiation menopause on relapse and 73% of the
postmenopausal control patients had TAM on relapse.
The incidence of side effects and second primary tumours is discussed as well as the possible effects of
varying the length of time over which adjuvant TAM is administered.
In November 1976, a controlled clinical trial was begun
using the drug tamoxifen (Nolvadex) as an adjuvant in the
treatment of operable breast cancer. The primary objective
was to find out if tamoxifen (TAM) when prescribed for a
period of one year following surgery would prolong overall
and/or disease free survival in pre- and postmenopausal
patients. All the patients were treated at the Christie Hospi-
tal and Holt Radium Institute, Manchester.
The seven year results have been previously published
(Ribeiro & Swindell, 1985). The present paper presents the
ten year status.
Patients and methods
These have been described in detail previously and will only
be summarised here.
Patients aged 35-70 years with operable breast carcinoma
were eligible (TI-T3a, NI-N2b, MO). Any of three types of
operation were performed: (1) a radical mastectomy; (2) a
simple mastectomy only; (3) a simple mastectomy with node
sampling. Patients with positive nodes on histology and
those with Stage III disease received postoperative radiother-
apy. Following surgery, premenopausal patients were ran-
domly allocated to either an irradiation menopause or
tamoxifen (TAM) 20mg daily for one year. Patients were
regarded as premenopausal if they were actively menstruat-
ing or within 2 years of the natural menopause, or had
previously had an hysterectomy only and were aged less than
55 years. Postmenopausal women were randomised to either
TAM 20mg daily for one year or no further treatment.
Every patient had a full blood count, biochemical profile
and a modified skeletal survey.
At the start of the trial, endocrine receptor assays were
not generally available, so data is not available for analysis.
No patients have been lost to follow-up. Survival curves
were calculated by the life table method. Differences between
curves were examined using the log-rank test.
Results
The trial began in November 1976 and closed when 1005
patients had been entered in June 1982. Forty-four patients,
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22 randomised to TAM and 22 randomised to the irradia-
tion menopause/control group were excluded soon after
randomisation because of major protocol violations. The
majority of these were patients who were found to have
metastatic disease. The remainder did not have a mastec-
tomy, had previous systemic therapy or were over age. A
total of 961 patients were therefore available for the present
analysis.
Of the patients allocated to TAM, 94% completed a full
year on a dosage of 20mg daily, 2% completed a year on a
reduced dose of 10mg daily and 4% stopped the drug due to
side-effects. Drug compliance was tested by giving the
patients a measured number of tablets, and making sure they
returned to source for a further supply. Some patients were
also asked to supply blood samples for estimation of plasma
TAM levels.
As only 26% of the patients had an axillary clearance
done, it would not be statistically accurate to assess the
survival of sub-groups based on the number of nodes
involved by tumour. Instead, the series of patients will be
looked at within the broad grouping of premenopausal and
postmenopausal women and then further analysed in the
following three categories; (a) patients whose node status is
unknown, (b) patients with histologically negative axillae, (c)
those with histologically positive axillae. It is accepted that
for those patients that had node sampling only, the node
negative status may not always be accurate.
Premenopausal patients
This group comprises 373 patients, of whom 70% had
clinical Stage I carcinomas, 21% Stage II and 9% Stage III
disease. Of the 373 patients, 199 were randomly allocated to
the TAM group and 174 to have an irradiation menopause.
The median age of the premenopausal patients was 45 years.
Survival
The overall survival for the 373 premenopausal patients is
shown in Figure 1. The overall 10 year survival of the 199
patients in the TAM group was 63% vs. 56% for the
irradiation menopause group; the differnce is not statistically
significant (P=0.40).
When survival is analysed within the three node categories
outlined above, then the most marked trend in favour of
TAM is seen in the node negative group as shown in Figure
2. Only four patients have died in the TAM group giving a
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temporary amenorrhoea, all but one had a return of regular
menstruation within one year of stopping TAM. A total of
19% went through a permanent menopause with no return
of menstruation following discontinuation of TAM, and 3%
developed menorraghia. The majority of the latter patients
had undiagnosed fibroids in the uterus.
Postmenopausal patients
Of the postmenopausal women, 282 were randomised to
receive TAM and 306 to the control group. Figure 3 shows
the curves for overall survival at 10 years for the two groups
(P=0.73).
When survival curves are compared in the three subgroups
by node status, there is a consistent trend in favour of TAM
but never approaching statistical significance in any
sub-group.
Table I shows an analysis done to assess the effect of TAM
on the occurrence of events using the whole series of 961
evaluable patients. An event has been defined previously as
the first evidence of relapse, whether it be local recurrence or
distant metastases or death before a relapse is recorded.
Local recurrence was only counted if it preceded distant
metastases. In Table I it will be seen that patients treated
with TAM fared substantially better and though the differ-
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93% ten year survival vs. 82% in the irradiation menopause
group; however this is still not statistically significant
(P=0.09).
The overall and disease-free survival of premenopausal
patients given TAM whose menstruation was unaffected was
compared with the survival of those whose periods were
affected in some way. There was no significant difference in
the survival of these two groups of patients.
Effects on periods
All 174 patients prescribed an irradiation menopause deve-
loped hot flushes subsequently; 6 patients had recurrent
periods and had to have further radiation.
In the actively menstruating patients prescribed TAM,
50% had no effect on their periods, and 28% had irregular
periods or temporary amenorrhoea. Of those who developed
Figure 3 Overall survival of 588 postmenopausal patients at 10
years.
Table I Log rank analysis of events in 961 patients by lymph node
status
Events
Node status Group Pts. Obs. exp. OIE
Negative TAM 146 35 40.14 0.87
Irrad. menop.
Control f 151 46 40.86 1.13
Positive TAM 176 86 96.29 0.89
Irrad. menop.
Control 173 99 88.71 1.12
Not known TAM 159 60 61.64 0.97
Irrad. menop. l
Control J 156 57 55.36 1.03
ALL TAM 481 181 198.06 0.91
Irrad. menop. 480 202 184.94 1.09
x2=3.08; 1 df; P=0.07.
6U,
0
.C_
Ln
0
100
80-
cn
0
U/) >-
v
Figure 2 Overall survival
patients.CHRISTIE HOSPITAL TAMOXIFEN TRIAL 603
ence was not statistically significant (P=0.07) it must be
remembered that the 'controls' included the patients treated
with an irradiation menopause.
Treatment at relapse
It was difficult to insist on cross-over hormonal treatment
for premenopausal patients as often these patients had
rapidly progressing disease when they relapsed. Of those
patients originally allocated to TAM, 47% had an irradia-
tion menopause on relapse and 19% were represcribed
TAM. Only 18% of the irradiation menopause group had
TAM subsequently, the majority having chemotherapy. In
the postmenopausal women, on the other hand, the disease
at relapse was much more slowly progressive and 73% of the
control patients were given TAM subsequently. Of the
remainder, 25% were represcribed TAM; these were patients
who did not relapse for at least 2 years following discontin-
uation of adjuvant TAM.
General side effects
Both in pre- and post menopausal women, the side effects of
TAM were minimal. A total of 2% of women required to
reduce the dose to 10mg daily and 4% stopped the drug in
less than a year. None of the patients prescribed TAM on
relapse required to modify the dose or stop the drug. The
effects of TAM on menstruation have been noted above.
Second primary tumours
Table II shows the incidence of second malignancies occur-
ring in premenopausal women within the TAM and irradia-
tion menopause groups. It can be seen that there is no
significant difference in the incidence between the two
groups. Table III show the incidence in the postmenopausal
women and again there is no significant difference between
TAM treated patients and controls. Furthermore there does
not appear to be any specific increase in cancers of target
endocrine organs in patients treated with TAM.
Discussion
The present paper continues to show that patients treated
with TAM have fewer events over the follow-up period
compared to non-TAM treated patients. However at 10
years this difference is not statistically significant as it was at
7 years of follow-up. The TAM treated premenopausal
patients may have had a significantly better disease free
survival compared with a true control group given no
adjuvant treatment, but it was considered unethical to have
such a group when the trial was initiated.
At the inception of the trial, there was no reliable evidence
to suggest how long TAM should have been prescribed on
an adjuvant basis, so for the purposes of the trial a period of
one year was chosen on an empirical basis. Since that time,
evidence has been emerging that strongly suggests that TAM
given for two years or more will make a significant differ-
ence to overall and disease free survival of treated patients.
Table II Incidence of second primary
tumours pre-menopausal
Allocated group
Type TAM Irradmenop.
Breast 2 1
Stomach 1 0
Thyroid 1 0
Cervix 0 1
Lymphoma 0 1
Total 4/199=2% 3/174=1.7%
Table III Incidence of second primary
tumours post menopausal
Allocated group
Type TAM Control
Breast 6 7
Cervix 1 2
Endometrium 1 1
Rectum 2 1
Bladder 1 2
Skin 1 1
Stomach 2 0
Ovary 1 0
Colon 1 0
Thyroid 0 1
Total 16/282=5.6% 15/306=5%
Firstly, in the 6 year results of the NATO Trial of
Adjuvant Tamoxifen (NATO 1985), it was shown that TAM
given for two years, produced a highly significant reduction
in mortality and an equally significant prolongation of the
disease free interval in treated patients compared to controls
(P=0.0001).
More recently, in a Scottish Breast Cancer Trial (MRC,
1987) it was shown that patients treated with TAM over a
period of 5 years had a highly significant relapse free
survival when compared to controls (P=0.0001).
Some laboratory work on the duration of TAM therapy
has also been published (Jordan et al., 1980). These workers
compared a short course of TAM (50jug daily for 4 weeks)
with continuous therapy administered to rats with DMBA-
induced mammary carcinoma. In the experiment, the major-
ity of the rats given continuous therapy remained tumour-
free unlike those on the short course. The workers felt that
while there may be fundamental differences between the rat
model and human breast carcinoma, the principles for the
control of hormone-dependent growth may be similar.
Further clinical trials are now in progress comparing the
administration of TAM for two years or more with TAM
prescribed for life. The long term results of these trials will
be awaited with interest.
Our thanks are due to the clinicians who participated in the trial, a
list of whom has been previously published.
Thanks are also due to the Dept. of medical illustration and to
Mrs P.A. Jones for secretarial assistance.
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